BACKGROUND: Vascular @entity1066 are commonly seen in daily practice at all levels of care and have great impact at personal, professional and social levels with a high cost in terms of @entity1 and material resources. Given that the application of autologous platelet rich plasma has been shown to decrease healing times in various different studies in the hospital setting, we considered that it would be interesting to assess the efficacy and feasibility of this treatment in primary care. The objectives of this study are to assess the potential efficacy and safety of autologous platelet rich plasma for the treatment of @entity3179 compared to the conventional treatment (moist wound care) in primary care @entity1 with @entity4096 (C, clinical class, E, aetiology, A, anatomy and P, pathophysiology classification C6). DESIGN: We will conduct a phase III, open-label, parallel-group, multicentre, randomized study. The subjects will be 150 @entity1 aged between 40 and 100 years of age with an at least 2-month history of a vascular venous @entity1066 assigned to ten primary care centres. For the treatment with autologous platelet rich plasma, all the following tasks will be performed in the primary care setting: blood collection, centrifugation, separation of platelet rich plasma, activation of coagulation adding @entity12374 and application of the @entity3669 topically after gelification. The control group will receive standard moist wound care. The outcome variables to be measured at baseline, and at weeks 5 and 9 later include: reduction in the @entity1066 area, Chronic @entity4096 Quality of Life Questionnaire score, and percentage of @entity1 who require wound care only once a week. DISCUSSION: The results of this study will be useful to improve the protocol for using platelet rich plasma in chronic vascular @entity1066 and to favour wider use of this treatment in primary care. TRIAL REGISTRATION: Current Controlled Trials NCT02213952.

Efficacy and safety of autologous platelet rich plasma for the treatment of vascular XXXX in primary care: Phase III study.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulcers'] @entity3179 :: ('MESH:D014647', 'Disease') :: ['venous ulcers'] @entity3669 :: ('5621', 'Gene') :: ['PRP'] @entity4096 :: ('MESH:D014689', 'Disease') :: ['Venous Insufficiency', 'chronic venous insufficiency'] @entity12374 :: ('MESH:D002122', 'Chemical') :: ['calcium chloride']
@entity1066 :: (MESH:D014456,Disease) :: ['ulcers']
